{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05881993",
            "orgStudyIdInfo": {
                "id": "CBP-4888-100"
            },
            "organization": {
                "fullName": "Comanche Biopharma",
                "class": "INDUSTRY"
            },
            "briefTitle": "Study of CBP-4888 in Healthy, Non-Pregnant Female Subjects",
            "officialTitle": "A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CBP-4888 in Healthy, Non-Pregnant Female Subjects",
            "therapeuticArea": [
                "Other"
            ],
            "study": "study-of-cbp-in-healthy-non-pregnant-female-subjects"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-01",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-05-22",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-03",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-04",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-05-09",
            "studyFirstSubmitQcDate": "2023-05-19",
            "studyFirstPostDateStruct": {
                "date": "2023-05-31",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-01-23",
            "lastUpdatePostDateStruct": {
                "date": "2024-01-24",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Comanche Biopharma",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is a Phase I, first-in-human, single-center, randomized, double-blind, placebo-controlled, single ascending dose study to evaluate the safety, tolerability, and PK of ascending doses of CBP-4888.",
            "detailedDescription": "This study will involve female subjects meeting all inclusion criteria and no exclusion criteria. Cohorts of CBP-4888 are planned to be investigated in a sequential dose-escalation manner. Each cohort of subjects will be randomized to CBP-4888 to placebo and administered a single subcutaneous dose."
        },
        "conditionsModule": {
            "conditions": [
                "Healthy Volunteer Study"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "EARLY_PHASE1"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "QUADRUPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 15,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "CBP-4888",
                    "type": "EXPERIMENTAL",
                    "description": "CBP-4888 administered once as a subcutaneous dose.",
                    "interventionNames": [
                        "Drug: CBP-4888"
                    ]
                },
                {
                    "label": "Placebo",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Normal Saline administered once as a subcutaneous dose.",
                    "interventionNames": [
                        "Other: Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "CBP-4888",
                    "description": "siRNA therapeutic",
                    "armGroupLabels": [
                        "CBP-4888"
                    ]
                },
                {
                    "type": "OTHER",
                    "name": "Placebo",
                    "description": "Normal Saline",
                    "armGroupLabels": [
                        "Placebo"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Adverse Events",
                    "description": "Number of participants with treatment-related adverse events",
                    "timeFrame": "30 days"
                },
                {
                    "measure": "Pain at Site of Injection",
                    "description": "Assessment of Pain on a 5 point scale (none, mild, moderate, severe or potentially life threatening)",
                    "timeFrame": "30 days"
                },
                {
                    "measure": "Tenderness at Site of Injection",
                    "description": "Assessment of Tenderness on a 5 point scale (none, mild, moderate, severe or potentially life threatening)",
                    "timeFrame": "30 Days"
                },
                {
                    "measure": "Erythema at Site of Injection",
                    "description": "Assessment of Erythema on a 5 point scale (none, mild, moderate, severe or potentially life threatening)",
                    "timeFrame": "30 days"
                },
                {
                    "measure": "Swelling at Site of Injection",
                    "description": "Assessment of Swelling on a 5 point scale (none, mild, moderate, severe or potentially life threatening)",
                    "timeFrame": "30 Days"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Cmax of CBP-4888",
                    "description": "Peak Plasma Concentration",
                    "timeFrame": "30 days"
                },
                {
                    "measure": "AUC of CBP-4888",
                    "description": "Area Under the Plasma Concentration Versus Time Curve",
                    "timeFrame": "30 days"
                },
                {
                    "measure": "Tmax of CBP-4888",
                    "description": "Time to maximum plasma concentration",
                    "timeFrame": "30 days"
                }
            ],
            "otherOutcomes": [
                {
                    "measure": "Pharmacodynamics",
                    "description": "Concentraion of sFLt-1",
                    "timeFrame": "30 days"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Healthy non-pregnant female subjects\n* Body mass index (BMI) \u2265 18.5 and \u2264 35.0 kg/m2\n* Medically healthy, defined as having no clinically significant abnormal screening results including clinical laboratory evaluations, medical history, vital signs, ECG, and physical examination as deemed by the Investigator.\n\nExclusion Criteria:\n\n* Screening blood pressure \\< 100/60 mmHg or \\> 140/90 mmHg\n* Screening heart rate that is \\< 40 bpm or \\> 99 bpm\n* Clinically significant ECG abnormality at screening\n* Used prescription medication within 14 days prior to dosing\n* Used over the counter (OTC) medications (including herbal products, nutritional supplements, dietary supplements, and/or vitamins) within 7 days prior to dosing\n* Donated blood or had significant blood loss within 56 days prior to dosing",
            "healthyVolunteers": true,
            "sex": "FEMALE",
            "genderBased": true,
            "genderDescription": "females",
            "minimumAge": "18 Years",
            "maximumAge": "50 Years",
            "stdAges": [
                "ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Jim Joffrion",
                    "role": "CONTACT",
                    "phone": "800-876-8619",
                    "email": "jim@comanchebiopharma.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Allison August, MD",
                    "affiliation": "Chief Medical Officer",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Comanche Biopharma Clinical Research Site #1",
                    "status": "RECRUITING",
                    "city": "San Antonio",
                    "state": "Texas",
                    "zip": "78217",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Recruitment Department",
                            "role": "CONTACT",
                            "phone": "210-635-1515",
                            "email": "participate@worldwide.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.42412,
                        "lon": -98.49363
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        }
    },
    "hasResults": false
}